<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434096</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5749</org_study_id>
    <nct_id>NCT00434096</nct_id>
  </id_info>
  <brief_title>Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)</brief_title>
  <official_title>A Randomized Double-blind, Placebo-controlled, Parallel-group, Fixed Single-dose Regimen (SR141716 20 mg), Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Patients With Dyslipidemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of SR141716 compared to placebo&#xD;
      on body weight and triglycerides changes over a period of 52 weeks.&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on&#xD;
           HDL-cholesterol and visceral fat area.&#xD;
&#xD;
        -  To evaluate the safety of SR141716 compared to placebo over a period of 104 weeks.&#xD;
&#xD;
        -  To evaluate the pharmacokinetics of SR141716.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision taken in light of demands by certain national health authorities&#xD;
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>body weight: relative change from baseline</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>triglycerides: relative change from baseline</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol ;visceral fat area</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">915</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rimonabant (SR141716)</intervention_name>
    <description>oral administration once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 25 kg/m²&#xD;
&#xD;
          -  Visceral Fat Area (VFA) &gt; 100 cm²&#xD;
&#xD;
          -  Triglycerides (TG) &gt; 150 mg/dL and &lt; 700 mg/dL, and/or HDL-cholesterol &lt; 40&#xD;
             mg/dL(Dyslipidemia)&#xD;
&#xD;
          -  At least 1 criteria of the following 2 comorbidities:&#xD;
&#xD;
               -  Impaired Glucose Tolerance or Type 2 diabetes&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a secondary obesity.&#xD;
&#xD;
          -  Patients who have received the diet therapy for less than 8 weeks before start of the&#xD;
             observation period.&#xD;
&#xD;
          -  Patients whose body weight changed by more than the variation of ± 2kg for screening&#xD;
             period.&#xD;
&#xD;
          -  Low compliance to drug intake (&lt; 80%) and dietary instruction during the observation&#xD;
             period.&#xD;
&#xD;
          -  Patients with type 1 diabetes.&#xD;
&#xD;
          -  Patients with a primary hyperlipidemia (i.e., familial hypercholesterolemia, familial&#xD;
             combined hyperlipidemia and familial type III hyperlipidemia).&#xD;
&#xD;
          -  Patients with a LDL-cholesterol &gt; 190 mg/dL at any of Weeks -8 or -4.&#xD;
&#xD;
          -  Patients with a secondary hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>July 17, 2009</last_update_submitted>
  <last_update_submitted_qc>July 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Obesity disease</keyword>
  <keyword>cannabinoid-1 receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

